antibodies-online.com

Datasheet for ABIN2725552

MATR3 Protein (Transcript Variant 2) (Myc-DYKDDDDK Tag)

1 Image | 1 Publication

Go to Product page

Overview

Quantity:	20 µg
Target:	MATR3
Protein Characteristics:	Transcript Variant 2
Origin:	Human
Source:	HEK-293 Cells
Protein Type:	Recombinant
Purification tag / Conjugate:	This MATR3 protein is labelled with Myc-DYKDDDDK Tag.
Application:	Antibody Production (AbP), Standard (STD)

Product Details

Characteristics:	• Recombinant human Matrin-3 (transcript variant 2) protein expressed in HEK293 cells. • Produced with end-sequenced ORF clone
Purity:	> 80 % as determined by SDS-PAGE and Coomassie blue staining

Target Details

Target:	MATR3
Alternative Name:	Matrin-3 (MATR3 Products)
Background:	This gene encodes a nuclear matrix protein, which is proposed to stabilize certain messenger RNA species. Mutations of this gene are associated with distal myopathy 2, which often includes vocal cord and pharyngeal weakness. Alternatively spliced transcript variants, including read-through transcripts composed of the upstream small nucleolar RNA host gene 4

Target Details

	(non-protein coding) and matrin 3 gene sequence, have been identified. Pseudogenes of this gene are located on chromosomes 1 and X.
Molecular Weight:	94.4 kDa
NCBI Accession:	NP_061322

Application Details

Application Notes:	Recombinant human proteins can be used for: Native antigens for optimized antibody production Positive controls in ELISA and other antibody assays
Comment:	The tag is located at the C-terminal.
Restrictions:	For Research Use only

Handling

Concentration:	50 µg/mL
Buffer:	25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10 % glycerol.
Storage:	-80 °C
Storage Comment:	Store at -80°C. Thaw on ice, aliquot to individual single-use tubes, and then re-freeze immediately. Only 2-3 freeze thaw cycles are recommended.

Publications

Product cited in:	Guo, Li, Xiang, Huang, Ma, Wang, Gong: "Nutlin-3 plus tanshinone IIA exhibits synergetic anti-leukemia effect with imatinib by reactivating p53 and inhibiting the AKT/mTOR pathway in Ph+ ALL." in: **The Biochemical journal**, Vol. 474, Issue 24, pp. 4153-4170, (2017) (PubMed).



Western Blotting

Image 1. Validation with Western Blot

